U.S. Markets closed

Jupiter Wellness, Inc. (JUPW)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4900-0.0500 (-3.25%)
At close: 4:00PM EDT
1.5200 +0.03 (2.01%)
After hours: 07:41PM EDT
Sign in to post a message.
  • R
    Russ
    In at $2.02
    Bullish
  • J
    Jose V
    News Release

    Jupiter Wellness Announces Multi-Year Distribution Agreement with Rigour International for Expansion in Asia
    Bullish
  • J
    Joe Ward
    Anything negative is a short anything positive a bag holder. Normal
  • D
    Dorian
    Remember company has five employees. Not too promising.
  • b
    bseae
    Any body here..
  • C
    Christian
    What is the redemption info for the warrants?
  • s
    scot
    Buying this dip
    Bullish
  • W
    Walter
    JUPW pretty clear this sell off is overdone

    Raised $$ will be reinvested, Rigour will bring in millions in revenue.

    Nice time to accumulate more
    Bullish
  • J
    Jobro
    I’m here and holding since January don’t know what to make of this but have no choice but to hold I’m not selling at a loss even if I have to wait a few years or more
    Bullish
  • T
    Thomas
    10 dollars soon
  • D
    Dennis
    This name could very well catch on. In the afternoon, when the Reddit crowd wakes up to this, it could catch on fire... Also, there is, in fact, a good reason for it to spike...
  • A
    Alan
    Full-time employees: 5 lol
    Bearish
  • J
    Jose V
    New Press Release

    JUPITER, FL / July 13, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced a head-to-head trial comparing JW-100 lotion with Eucrisa crisaborole ointment 2% for the treatment of patients with mild to moderate eczema (Atopic Dermatitis). Eucrisa is an FDA-approved topical non-steroidal lotion containing crisaborole approved for the treatment of mild to moderate eczema. JW-100 is a novel non-steroidal topical lotion containing cannabidiol (cbd) and Aspertame for the treatment of mild to moderate eczema.

    The head-to-head clinical trial which will evaluate superiority between JW-100 and Eucrisa in adult patients with mild-to-moderate eczema will be performed in collaboration with Applied Biology who has developed the protocols and will co-ordinate the multi-center trial. The Phase III multi-center trial will be a double-blinded placebo controlled trial.
    Bullish
  • M
    May
    so they buying justCBD
    that's a game changer if true
  • H
    Harry
    10+ this week
  • T
    Thomas
    $TKAT conversation
    Check $JUPW guys
    CBD company with great earnings, very low float, multiples websites, selling to big partners, having clinical trials on herpes, eczema with cbd products
  • J
    Jobro
    How is everyone today ?
  • m
    mike
    Hows everyone feeling today
  • J
    Jose V
    Today's press release

    JUPITER, FL / ACCESSWIRE / April 16, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced it has appointed Dr. Glynn Wilson as Chief Science Officer, Rich Miller as Chief Compliance Officer, and Ryan Allison as Chief Operating Officer. Over the past quarters, Jupiter has grown its CBD-based consumer wellness business to include 40 products across seven brands in six categories, while also advancing its clinical pipeline with three indications in Phase 1 equivalent studies and one indication ready for an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) based on a successful Phase 1 equivalent which met its primary endpoint.

    Dr. Glynn Wilson, who continues to serve as Chairman of the Board and was formerly Head of R&D at Jupiter, will now serve as Chief Science Officer overseeing Jupiter’s pipeline of clinical indications including eczema. Should JW-100 continue to show similar efficacy in advanced stage trials, Jupiter’s lead product candidate would address a $10 billion global market, in which a competing product is projected to reach $2 billion in annual sales. Dr. Wilson will guide the development strategy and clinical design for Jupiter’s CBD-based topical product candidates for indications including skin cancer, burns, and herpes cold sores, all of which are currently in Phase 1 equivalent human trials. Dr. Wilson was formerly Head of Drug Delivery at SmithKline Beecham and was Founder, CEO and Chairman of TapImmune, a developer of cancer vaccines.

    Rich Miller continues to serve as a Director for Jupiter and now moves into the newly created position of Chief Compliance Officer overseeing regulatory affairs for securities, CBD-based products, Jupiter’s subsidiaries, manufacturing, and international trade. As Jupiter expands through both organic growth and acquisition, Mr. Miller serves a critical role in assuring the Company defines best practices in innovation as a leader in its industry segments.

    Ryan Allison, formerly Vice President of Business Development, moves into the position of Chief Operating Officer overseeing growth as Jupiter capitalizes on unprecedented opportunities in the CBD pharma and wellness space. Mr. Allison is a strong leader who has been at the forefront of building high-performance, data-driven organizations and business infrastructure throughout his career across many industries including healthcare and the federal government. Earlier in his career Mr. Allison served at VMware where he was an early member of the cloud computing team and an instrumental player in securing a foothold in the infant cloud landscape, a market segment VMware continues to lead in today.

    "I am confident these new adjustments to our leadership team have Jupiter Wellness prepared for the explosive growth we are expecting to see in the CBD market. I am thrilled that we have access to such high caliber talent across our team as we step into our second quarter.," stated Brian John, CEO of Jupiter Wellness.
    Bullish
  • J
    Jeff
    This one is dead. Does anybody know exactly why they pulled the IPO completely? I believe that they couldn't even get enough buyers for the 1,000,000 shares.

    What does that tell you ?